A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

• Drug: Desvenlafaxine Succinate Sustained-Release
  
  Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
• Drug: Desvenlafaxine Succinate Sustained-Release
  
  Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
• Drug: Placebo
  
  Subjects randomized to the Placebo treatment arm will receive placebo tablets

• Experimental: Experimental Arm 1 - high dose
  
  Intervention: Drug: Desvenlafaxine Succinate Sustained-Release
• Experimental: Experimental Arm 2 - low dose
  
  Intervention: Drug: Desvenlafaxine Succinate Sustained-Release
• Placebo Comparator: Placebo Arm
  
  Intervention: Drug: Placebo

Inclusion Criteria:

• Age >=7 and <18 years of age
• Primary diagnosis of major depressive disorder (MDD)
• CDRS-R score >40

Exclusion Criteria:

• History of suicidal behavior or requires precaution against suicide
• Not in generally healthy medical condition
• History of psychosis or bipolar disorder
• Seizure disorder